Formulation and in vivo evaluation of chlorpropham (CIPC) oral formulations

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5222-5228

  Kuehl, Philip J ^a,c   Brenner, Tim ^b   Jain, Parijat K ^b   Karlage, Kelly ^b   Sepassi, Kia ^c   Yang, Gang ^c   Mayersohn, Michael ^b   Yalkowsky, Samuel H ^b   Myrdal, Paul B ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bioavailability; Chloropropham; Formulation; Oral drug delivery; Pharmacokinetics; SEDDS; Solubility

Indexed keywords

ALCOHOL; CHLORPROPHAM; DIMETHYL SULFOXIDE; GLYCEROL; MACROGOL 400; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 57349084177     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21384     Document Type: Article

References (13)

1. Camden JB. 1996. A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers. PCT Int Appl, 18 pp. CODEN: PIXXD2 WO 9632104 A1 19961017 CAN 126:1176 AN 1996:718343 CAPLUS.
2. Camden JB. 1996. A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals. PCT Int Appl, 16 pp. CODEN: PIXXD2 WO 9632103 A1 19961017 CAN 125:317335 AN 1996:716308 CAPLUS.
3. Camden JB. 1998. HIV and cancer treatment. PCT Int Appl, 41 pp. CODEN: PIXXD2 WO 9851303 A1 19981119 CAN 130:20546 AN 1998:764282 CAPLUS.
4. Camden JB. 2001. Method of treatment for cancer or viral infections with a N-chlorophenylcarbamate, or N-chlorophenylthiocarbamate. U.S., 13 pp. Cont.-in-part of U.S. Ser. No. 364,021. CODEN: USXXAM US 6177460 B1 20010123 CAN 134:95530 AN 2001:57228 CAPLUS.
5. Biobyte Corp. 1995-1999. CLogP for Windows. Version 4.0. Biobyte Corp., Claremont, CA.
6. WinNonLin. 1998-2006. WinNonLin Professional. Version 5.1. Pharsight WinNonlin Corp., Mountain View, CA.
7. Stata. 2001. Release 7.0. College Station, TX: Stata Corporation.
8. Pouton CW. 1997. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 25:47-58.
9. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. 2004. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 30:221-229.
10. Wei L, Sun P, Nie S, Pan W. 2005. Preparation and evaluation of SEDDS and SMEDDS containing Carvedilol. Drug Dev Ind Pharm 31:785-794.
11. Hong JY, Kim JK, Song YK, Park JS, Kim CK. 2006. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 110:332-338.
12. Kim CK, Cho YJ, Gao ZG. 2001. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J Control Release 70:149-155.
13. Gershanik T, Benita S. 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50:179-188.